Opiant Pharmaceuticals (NASDAQ:OPNT) Director Thomas T. Thomas sold 4,300 shares of Opiant Pharmaceuticals stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $18.35, for a total transaction of $78,905.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Opiant Pharmaceuticals opened at $17.49 on Wednesday, according to Marketbeat.com. Opiant Pharmaceuticals has a 12-month low of $17.77 and a 12-month high of $17.77. The company has a market capitalization of $46.77 million, a PE ratio of 5.95 and a beta of -0.57.
A hedge fund recently raised its stake in Opiant Pharmaceuticals stock. Spark Investment Management LLC grew its holdings in Opiant Pharmaceuticals (NASDAQ:OPNT) by 46.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,400 shares of the technology company’s stock after purchasing an additional 6,500 shares during the period. Spark Investment Management LLC owned approximately 0.99% of Opiant Pharmaceuticals worth $468,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 3.71% of the company’s stock.
Separately, ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.